NCT06198868 MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
| NCT ID | NCT06198868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jiangsu Cancer Institute & Hospital |
| Condition | Non-small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-02-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent must be signed before implementing any enrollment-related procedures; 2. Age ≥18 years old; 3. Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)； 4. There is no special restriction on the source of genetic test report. 5. According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion. 6. Have not received any previous systemic antitumor therapy for advanced diseases. 7. No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system. 8. ECOG score: 0-1; 9. Expected survival time \> 3 months. Exclusion Criteria: 1. Received surgical treatment for lung tumors. 2. Received neoadjuvant chemotherapy or radiotherapy. 3. Received cellular therapy within the last 1 year. 4. Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases. 5. Participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06198868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06198868 currently recruiting?
Yes, NCT06198868 is actively recruiting participants. Contact the research team at rong_yin@njmu.edu.cn for enrollment information.
Where is the NCT06198868 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06198868 clinical trial?
NCT06198868 is sponsored by Jiangsu Cancer Institute & Hospital. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.